Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity

Vaccine

Volumn 28, Issue 22, 2010, Pages 3827-3840

  Monath, Thomas P ^a   Lee, Cynthia K ^b   Julander, Justin G ^c   Brown, Alicja ^b   Beasley, David W ^d   Watts, Douglas M ^d   Hayman, Edward ^b   Guertin, Patrick ^b   Makowiecki, Joseph ^b   Crowell, Joseph ^b   Levesque, Philip ^b   Bowick, Gavin C ^d   Morin, Merribeth ^b   Fowler, Elizabeth ^b   Trent, Dennis W ^b  

^a Kleiner Perkins Caufield & Byers   (United States)

^b Xcellerex Inc   (United States)

^c UTAH STATE UNIVERSITY   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Immune response; Inactivated vaccine; Yellow fever

Indexed keywords

ALUMINUM HYDROXIDE; INACTIVATED VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PROPIOLACTONE; UNCLASSIFIED DRUG; XRX 001; YELLOW FEVER VACCINE;

ADSORPTION KINETICS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HAMSTER; HEPATITIS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; LOW DRUG DOSE; LYMPHADENOPATHY; MACACA; MALE; MONKEY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; RAT; REPEATED DRUG DOSE; SERODIAGNOSIS; SINGLE DRUG DOSE; VACCINE PRODUCTION; VIREMIA; VIRION; VIRUS INACTIVATION; VIRUS NEUTRALIZATION; VIRUS STRAIN; WEIGHT REDUCTION; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CRICETINAE; FEMALE; MACACA FASCICULARIS; MALE; MESOCRICETUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS; VACCINES, INACTIVATED; VERO CELLS; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 77952322608     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.03.023     Document Type: Article

References (57)

1. Monath T.P. Treatment of yellow fever. Antiviral Res 78 (2008) 116-124
2. Robertson S.E., Hull B.P., Tomori O., Bele O., LeDuc J.W., and Esteves K. Yellow fever: a decade of reemergence. JAMA 276 (1996) 1157-1162
3. Theiler M., and Smith H.H. Effect of prolonged cultivation in vitro upon pathogenicity of yellow fever virus. J Exp Med 65 (1937) 767-786
4. Theiler M., and Smith H.H. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med 65 (1937) 787-800
5. Barrett A.D., and Teuwen D.E. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol 21 (2009) 308-313
6. Centers for Disease Control and Prevention, Atlanta GA. Biologics Surveillance Summary; 2007.
7. Monath T.P., Cetron M., and Teuwen D. Yellow Fever. In: Plotkin S., Orenstein W., and Offit P. (Eds). Vaccines. 5th Edit (2008), Elsevier, Saunders 959-1055
8. ®) in a Phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 66 (2002) 533-541
9. Martin M., Tsai T.F., Cropp C.B., et al. Multisystemic illness in elderly recipients of yellow fever vaccine report of four cases. Lancet 358 (2001) 98
10. Vasconcelos P.F., Luna E.J., Galler R., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358 (2001) 91-97
11. Chan R.C., Penney D.J., Little D., Carter I.W., Roberts J.A., and Rawlinson W.D. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358 (2001) 121-122
12. Monath TP. Short report: suspected yellow fever vaccine associated viscerotropic adverse events (1973 and 1978), United States. Am J Trop Med Hyg; in press.
13. Monath T.P., and Cetron M.S. Prevention of yellow fever in persons travelling to the tropics. Clin Infect Dis 34 (2002) 1369-1378
14. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 101 (2007) 967-971
15. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 26 (2008) 6077-6082
16. Whittembury A., Ramirez G., Hernández H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 27 (2009) 5974-5981
17. Alexander L.N., Seward J.F., Santibanez T.A., Pallansch M.A., Kew O.M., Prevots D.R., et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA 292 (2004) 1696-1701
18. Lane J.M., Ruben F.L., Neff J.M., and Millar J.D. Complications of smallpox vaccination, 1968: national surveillance in the United States. N Engl J Med 281 (1969) 1201-1208
19. Tesh R.B., Guzman H., da Rosa A.P., et al. Experimental yellow fever virus infection in the golden hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies. J Infect Dis 183 (2001) 1431-1436
20. Ryman K.D., Ledger T.N., Weir R.C., Schlesinger J.J., and Barrett A.D. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J Gen Virol 78 (1997) 1353-1356
21. Guirakhoo F., Zhang Z., Chambers T.J., Delagrave S., Arroyo J., Barrett A.D.T., et al. Immunogenicity, genetic stability and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax™-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257 (1999) 363-372
22. Julander J.G., et al. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res 73 (2007) 140-146
23. Johnson B.W., Kosoy O., Hunsperger E., Beltran M., Delorey M., Guirakhoo F., et al. Evaluation of chimeric Japanese encephalitis and dengue viruses for use in diagnostic plaque reduction neutralization tests. Am J Trop Med Hyg 16 (2009) 1052-1059
24. Reed L.J., and Muench H. Simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493-497
25. Mutebi J.P., Wang H., Li L., Bryant J.E., and Barrett A.D.T. Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol 75 15 (2001) 6999-7008
26. Hindle E. A yellow fever vaccine. Brit Med J 1 (1928) 976-977
27. Gordon J., and Hughes T.P. Study of inactivated yellow fever virus as immunizing agent. J Immunol 30 (1936) 221-234
28. Gaspar L.P., Mendes Y.S., Yamamura A.M., Almeida L.F., Caride E., Gonçalves R.B., et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 150 (2008) 57-62
29. Schuller E., Klade C.S., Wölfl G., Kaltenböck A., Dewasthaly S., and Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study. Vaccine 27 (2009) 2188-2193
30. Zent O., Hennig R., Banzhoff A., and Bröker M. Protection against tick-borne encephalitis with a new vaccine formulation free of protein-derived stabilizers. J Travel Med 12 (2005) 85-93
31. Kelso J.M., Mootrey G.T., and Tsai T.F. Anaphylaxis from yellow fever vaccine. J Allergy Clin Immunol 103 (1999) 698-701
32. Koldijk M.H., Bogaards J.A., Kostense S., de Vocht M., Gijsbers L., Ter Haak M., et al. A sensitive cell-based assay for the detection of residual infectious West Nile virus. Vaccine 25 (2007) 6872-6881
33. Offitt P.A. The cutter incident (2005), Yale Univ Press, New Haven 238
34. Jones R.G., Liu Y., Rigsby P., and Sesardic D. An improved method for development of toxoid vaccines and antitoxins. J Immunol Methods 337 (2008) 42-48
35. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Viard M., Aitichou M., et al. Ebola virus inactivation with preservation of antigenic and structural integrity by a photoinducible alkylating agent. J Infect Dis 196 Suppl. 2 (2007) S276-S283
36. Perrin P., and Morgeaux S. Inactivation of DNA by β-propiolactone. Biologicals 23 (1995) 207-211
37. LoGrippo G.A., and Hartman W. Antigenicity of beta-propiolactone inactivated virus vaccines. Ann NY Acad Sci 75 (1955) 123-128
38. Bachmann M.F., Bast C., Hengartner H., and Zinkernagel R.M. Immunogenicity of a viral model vaccine after different inactivation procedures. Med Microbiol Immunol 183 (1994) 95-104
39. Bachmann M.F., Kundig T.M., Kalberer C.P., Hengartner H., and Zinkernagel R.M. Formalin inactivation of vesicular stomatitis virus impairs T-cell but not T-help-independent B-cell responses. J Virol 67 (1993) 3917-3922
40. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198 (2008) 500-507
41. Pulendran B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nature Rev Immunol 9 (2009) 1-7
42. Belsher J.L., Gay P., Brinton M., DellaValla J., Ridenour R., Lanciotti R., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25 (2007) 8480-8485
43. Kengsakul K., Sathirapongsasuti K., and Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85 (2002) 131-134
44. Barwick R. Eidex for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet 364 (2004) 936
45. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., and Ryman K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 5 October (10) (2009) e1000614
46. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., and Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453 (2008) 1122-1126
47. Xiao S.Y., et al. Experimental yellow fever virus infection in the Golden hamster (Mesocricetus auratus). II. Pathology. J Infect Dis 183 (2001) 1437-1444
48. Querec T.D., Akindy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10 (2009) 116-125
49. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205 (2008) 3119-3131
50. Scherer C.A., Magness C.L., Steiger K.V., Poitinger N.D., Caputo C.M., Miner D.G., et al. Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infections. Vaccine 25 (2007) 6458-6473
51. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203 (2006) 413-424
52. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28 (2008) 710-722
53. Cao W., Manicassamy S., Tang H., Kasturi S.P., Pirani A., Murthy N., et al. Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway. Nat Immunol 9 (2008) 1157-1164
54. Mason R.A., Tauraso N.M., Spertzel R.O., and Ginn R.K. Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25 (1973) 539-544
55. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant vaccine against West Nile virus. Proc Natl Acad Sci (USA) 103 (2006) 6694-6699
56. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine: phase I clinical trial for safety and immunogenicity, effect of yellow fever pre-immunity in induction of long lasting neutralizing antibody response to all 4 dengue serotypes after one dose of ChimeriVax™-DEN2 vaccine. Hum Vaccines 2 (2006) 60-67
57. Hombach J., Solomon T., Kurane I., Jacobson J., and Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines. WHO, Geneva, 2-3 September, 2004. Vaccine 23 (2005) 5205-5211